Printer Friendly

T CELL SCIENCES NAMES JOHN T. MUNSON TO BOARD OF DIRECTORS

 T CELL SCIENCES NAMES JOHN T. MUNSON TO BOARD OF DIRECTORS
 CAMBRIDGE, Mass., June 16 /PRNewswire/ -- T Cell Sciences, Inc., (NASDAQ: TCEL), today announced that John Patrick Munson, recently retired senior vice president of Syntex Corporation and president Syntex Pharmaceuticals International Ltd., has joined the company as a member of the board of directors. His appointment increases the number of board members to eight.
 Munson's career at Syntex spanned 23 years. He was president Syntex Pharmaceuticals International Ltd. from 1985-1992. From 1977-1985 he was vice president Europe and from 1970-1977 he was managing director United Kingdom. During his tenure as president of Syntex Pharmaceuticals International, this segment of Syntex reported over a 100 percent increase in sales and operating profits. Prior to joining Syntex, Munson held various finance and general management positions.
 "Mr. Munson's considerable operational success in running an important segment of Syntex Corporation will be of great value as we develop T Cell Sciences into a fully integrated biopharmaceutical company," said Alan W. Tuck, president and chief executive officer of T Cell Sciences. "Mr. Munson's skills and worldwide perspective complement the skills of the existing board members and will strengthen the advisory contributions made by the board to the company."
 Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, an 84 percent owned subsidiary of T Cell Sciences, develops, manufactures and markets highly innovative diagnostic and research products around the world.
 -0- 6/16/92
 /CONTACT: Alan W. Tuck, president and chief executive officer, or Susan Primrose, manager, corporate development and communications of T Cell Sciences, Inc., 617-621-1400/
 (TCEL) CO: T Cell Sciences, Inc. ST: Massachusetts IN: MTC SU: PER


TM -- NE007 -- 0594 06/16/92 10:46 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1992
Words:304
Previous Article:PRISM ENTERTAINMENT PRE-TAX PROFITS SHOW $1 MILLION TURNAROUND IN FIRST QUARTER ON 168 PERCENT SALES INCREASE
Next Article:AEROQUIP NAMES MARANO VICE PRESIDENT - NEW BUSINESS DEVELOPMENT/CHIEF TECHNICAL OFFICER
Topics:


Related Articles
CULBRO ANNOUNCES DIVIDEND
CONVEX NAMES ERICH BLOCH TO BOARD OF DIRECTORS
APPLIED BIOSCIENCE INTERNATIONAL INC. ELECTS SWEP T. DAVIS TO BOARD OF DIRECTORS AND APPOINTS HIM PRESIDENT, ENVIRONMENTAL SCIENCES GROUP
APPLIED BIOSCIENCE INTERNATIONAL INC. ANNOUNCES STOCK REPURCHASE PROGRAM OF UP TO 1 MILLION SHARES OF COMMON STOCK
FDA AUTHORIZES CLINICAL TESTING OF SECOND AGOURON ANTI-TUMOR DRUG
An investigation of a thymidylate synthase residue at position 163 in vertebrate species. (South Carolina Junior Academy Of Sciences Abstracts).
Celmed BioSciences to acquire NewBiotics of San Diego; Celmed strengthens its oncology portfolio and positions itself for future growth.
/C O R R E C T I O N -- CELMED BIOSCIENCES INC./; In MO267 transmitted this morning at 8:30e, an error occurred in the fourth line of the third...
Unprecedented Cross Institute Collaboration on Behalf of Patients with Tourette Syndrome.
Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters